Ex-Pur­due CEO stands to earn a huge wind­fall in No­var­tis' buy­out of the Med­i­cines Co

Mark Tim­ney, the ex-Pur­due Phar­ma CEO named in dozens of law­suits against the Oxy­Con­tin mak­er, stands to earn over $85 mil­lion in No­var­tis’s $9.7 bil­lion buy­out of the Med­i­cines Com­pa­ny.

Tim­ney joined the Med­i­cines Com­pa­ny as CEO in De­cem­ber, af­ter four years helm­ing the com­pa­ny broad­ly con­sid­ered to be at the heart of the opi­oid abuse cri­sis. SEC fil­ings from the time of his hire show he agreed to pur­chase $500,000 worth of stock at the time and was al­so grant­ed one mil­lion per­for­mance and time-vest­ed stock op­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER